The latest price target for Bellerophon Therapeutics Inc Com (New) (OTC:BLPH) was reported by HC Wainwright & Co. on June 6, 2023. The analyst firm set a price target for $2.00 expecting BLPH to rise to within 12 months (a possible 5455.56% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Bellerophon Therapeutics Inc Com (New) (OTC:BLPH) was provided by HC Wainwright & Co., and Bellerophon Therapeutics Inc Com (New) maintained their buy rating.

There is no last upgrade for Bellerophon Therapeutics Inc Com (New)

The last downgrade for Bellerophon Therapeutics Inc Com (New) happened on June 6, 2023 when Laidlaw & Co. changed their price target from N/A to N/A for Bellerophon Therapeutics Inc Com (New).

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bellerophon Therapeutics Inc Com (New), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bellerophon Therapeutics Inc Com (New) was filed on June 6, 2023 so you should expect the next rating to be made available sometime around June 6, 2024.

While ratings are subjective and will change, the latest Bellerophon Therapeutics Inc Com (New) (BLPH) rating was a maintained with a price target of $30.00 to $2.00. The current price Bellerophon Therapeutics Inc Com (New) (BLPH) is trading at is $0.04, which is out of the analyst’s predicted range.